Monthly Archives: October 2017

Halloween Happenings at Clery’s Boston

By | October 30, 2017

On Thursday, October 26 the ISPE Boston Area Chapter hosted the holiday-themed Annual Fall Social at Clery’s in Boston. Dressed in fun and creative costumes, ISPE members and guests mingled and munched on the delicious food provided in the “haunted” cellar. The event included a DJ accompanied by a fully-stocked photo booth. With the Halloween… Read More »

How to Deal with Difficult People – The Crucial Conversation

By | October 30, 2017

The following post was co-authored by Stephanie Fedak and Amber Galou, both of whom will be presenting at the Chapter’s upcoming educational program on November 8. It’s inevitable. We all have to deal with difficult people from time to time. And sometimes that difficult person is in a position of influence – you need that… Read More »

Just In – Product Show Photos

By | October 26, 2017

Once again our roving photographer has captured memorable highlights from the Product Show. Have a look and re-live the Chapter’s flagship event, find yourself and your friends, and be reminded why you never miss this unbeatable opportunity to meet, greet, learn and enjoy!

Product Show Keynote Highlights Oligonucleotides

By | October 26, 2017

The Product Show’s keynote speaker, Detlef Rethage, President of Nitto Avecia introduced a rapt audience to a regionally “hot” topic with his presentation  Oligonucleotide Therapeutics: The Promise and Reality from the Manufacturing Partner’s Prospective.  The crowd of ISPE members and guests learned the history, the science behind how “oligos” can regulate disease-causing proteins, and some… Read More »

RNAi Therapeutic Achieves First-Ever Positive Phase 3 Results

By | October 19, 2017

Leading RNAi therapeutics company, Alnylam Pharmaceuticals, and Sanofi Genzyme have announced that the Phase 3 study of patisiran met its primary efficacy endpoint and all secondary endpoints. Patisiran is an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy. “We are very proud to report the first ever positive Phase 3… Read More »

Alnylam and Vir Form Alliance to Advance RNAi Therapeutics for Infectious Diseases

By | October 19, 2017

Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection. As part of this agreement, the companies will advance Alnylam’s HBV program and also initiate a research collaboration for the development and advancement of up to… Read More »